Journal
FRONTIERS IN ONCOLOGY
Volume 11, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2021.751834
Keywords
AML; ICAM-1; NK; methylation; immune escape
Categories
Funding
- Chinese National Major Project for New Drug Innovation [2019ZX09201002003]
- National Natural Science Foundation of China [82030076, 2070161, 81970151, 81670162, 81870134]
- Shenzhen Science and Technology Foundation [JCYJ20190808163601776, JCYJ20200109113810154]
- Shenzhen Key Laboratory Foundation [ZDSYS20200811143757022]
- Sanming Project of Shenzhen [SZSM202111004]
Ask authors/readers for more resources
In patients with AML, the expression of ICAM-1 is silenced, but the hypomethylating agent can upregulate its expression, facilitating NK cells to kill AML cells. High expression of ICAM-1 can reverse AML immune evasion and activate NK cell function, suggesting a new strategy for AML treatment.
Acute myeloid leukemia (AML), a malignant disorder of hemopoietic stem cells. AML can escape immunosurveillance of natural killer (NK) by gene mutation, fusions, and epigenetic modification, while the mechanism is not clearly understood. Here we show that the expression of Intercellular adhesion molecule-1 (ICAM-1, CD54) is silenced in AML cells. Decitabine could upregulate ICAM-1 expression, which contributes to the NK-AML cell conjugates and helps NK cells kill AML cells. We also show that ICAM-1 high expression can reverse the AML immune evasion and activate NK cells function in vivo. This study suggests that a combination of the hypomethylating agent and NK cell infusion could be a new strategy to cure AML.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available